Clinically, PAH patients with Bmpr2 mutations have been shown to have early onset, poor prognosis, reduced vascular reactivity, impaired right ventricular function, and resistance to PAH-specific therapy [2, 4–7]. Here, BMPR2 is linked to pulmonary arterial hypertension.